

Contents

<i>Contributors</i>	iii
<i>Preface</i>	viii
<i>Acknowledgements</i>	xi

Section I Targets by Organ Site 1

Gerald S. Falchook and David S. Hong, Editors

Abbreviations	2
Adrenocortical Carcinoma— <i>Mouhammed Amir Habra, Aung Naing</i>	3
Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct)— <i>David S. Hong, Ahmed O. Kaseb, Goldy C. George</i>	4
Bladder Carcinoma (Urothelial Cancer)— <i>Arlene O. Siefker-Radtke</i>	6
Brain Tumors— <i>Vivek Subbiah</i>	
Glioblastoma/Malignant Gliomas	7
Medulloblastoma	9
Meningiomas	10
Other NF-Related Tumors	11
Breast Cancer— <i>Jennifer J. Wheeler</i>	
ER/PR+	12
HER2+	13
Triple-Negative/Basal/Metaplastic	15

Cervical Cancer— <i>Laura L. Holman, Siqing Fu, Shannon N. Westin</i>	16
Colorectal Cancer (Adenocarcinoma)— <i>David S. Hong, E. Scott Kopetz, Goldy C. George</i>	18
Esophageal Cancer (Squamous Cell)— <i>Mariela Blum Murphy, David S. Hong, Goldy C. George</i>	22
Gastric Cancer/Gastroesophageal Junction (Adenocarcinoma)— <i>Mariela Blum Murphy, David S. Hong, Goldy C. George</i>	23
Head and Neck Cancer— <i>Erminia Massarelli, Sangeeta Goswami, Sarina A. Piha-Paul</i>	
Squamous Cell—Oropharynx	25
Salivary Gland	26
Kidney (Renal Cell) Cancer— <i>Vivek Subbiah, Nizar M. Tannir</i>	27
Leukemia— <i>Radhika Kainthle, Tapan M. Kadia, Naveen Pemmaraju</i>	
Acute Myeloid Leukemia	30
Acute Lymphoblastic Leukemia	32
Chronic Myeloid Leukemia	33
Chronic Lymphocytic Leukemia	34
Myeloproliferative Neoplasm	35
Liver Cancer (Hepatocellular)— <i>Xiaochun Liu, Ahmed O. Kaseb</i>	29
Lung Cancer (Non-Small Cell)— <i>Daniel D. Karp, Lauren Averett Byers</i>	36
Lymphoma— <i>Xiaochun Liu, Jason R. Westin</i>	39
Melanoma— <i>Gerald S. Falchook, Scott Eric Woodman</i>	42
Multiple Myeloma— <i>Manojkumar Bupathi, Jatin J. Shah</i>	46
Ovarian Cancer— <i>Laura L. Holman, Siqing Fu, Shannon N. Westin</i>	48

Pancreatic Cancer (Ductal Carcinoma)— <i>David S. Hong, Milind Javle, Goldy C. George</i>	54
Prostate Cancer (Adenocarcinoma)— <i>Paul G. Corn</i>	55
Sarcoma (Gastrointestinal Stromal Tumors, GIST)— <i>Vivek Subbiah, Anthony Conley</i>	56
Skin Cancer (Basal Cell)— <i>Gerald S. Falchook, Scott Eric Woodman</i>	63
Testicular Cancer (Germ Cell Carcinoma)— <i>Vivek Subbiah and Lance C. Pagliaro</i>	64
Thymoma and Thymic Carcinoma— <i>Ralph G. Zinner</i>	65
Thyroid Cancer— <i>Maria E. Cabanillas, Manojkumar Bupathi</i>	
Anaplastic Carcinoma.....	70
Medullary Carcinoma.....	69
Papillary and Follicular Carcinoma.....	67
Uterine (Endometrial) Cancer— <i>Laura L. Holman, Siging Fu, Shannon N. Westin</i>	71

Section 2 Carcinogenesis from the Perspective of Targeted Therapy 83

Daniel D. Karp

Section 3 Molecular Targets and Pathways 112

Johnique T. Atkins and Filip Janku, Authors

Yong Wha Moon, Contributor

Angiogenesis.....	115
Angiogenesis Regulators.....	117

Targeting HIF-1 α	118	Targeting RAS.....	146
Receptor Tyrosine Kinases.....	119	Targeting BRAF Mutations.....	147
VEGFR and Targeting		Targeting MEK and MAPK.....	148
VEGFR.....	120	PI3K Pathway.....	149
FGFR and Targeting FGFR.....	121	Targeting PI3K Mutations.....	151
PDGFR and Targeting PDGFR.....	122	AKT Pathway.....	152
TIE Receptors Signaling.....	123	Targeting AKT Mutations.....	153
TIE Receptors.....	124	PTEN Alterations and	
IGF-1R and Insulin Receptor		TSC Mutations.....	154
Signaling.....	125	Targeting mTORC1 Complex.....	155
IGF-1R and Insulin Receptor.....	126	Targeting mTORC2 Complex.....	156
TGF α / β Pathway.....	127	JAK/STAT Pathway.....	157
EGFR Family of Receptors.....	129	Targeting JAK.....	159
EGFR Ligands.....	130	Hedgehog Signaling Pathway.....	160
EGFR Resistant and Sensitive		NOTCH Pathway.....	162
Mutations.....	131	Wnt Pathway.....	164
EGFR Inhibition.....	132	SRC Pathway.....	167
Targeting HER2.....	133	NF κ B Pathway.....	169
HGF Receptors: MET.....	134	Death Receptors and	
Targeting MET.....	135	Apoptosis.....	172
RET Receptor.....	136	Cell Cycle Regulation.....	175
Targeting RET.....	137	TP53.....	176
KIT Receptor.....	138	RB1.....	178
ALK Receptor.....	140	CDKN2A Regulation.....	180
ALK Alterations.....	141	BRCA.....	181
G Protein-Coupled Receptor		BRCA and PARP.....	182
Pathways.....	142	Aurora Kinases.....	183
RAS/MAPK Pathway.....	144	Immunotherapy.....	184

Section 4 Targeted Therapy Agents 189

xvii

Johnique T. Atkins and JoAnn D. Lim, Editors

Tiffany L. Jackson, Sarah Baldwin, Jenny R. Berry, Amy B. Patel,

Holly Kinahan, Laura Beatty, Tamara Griffey Barnes,

Fedricker D. Barber, and Lindsay Gaido, Contributors

Abiraterone Acetate (Zytiga).....	188	Cabozantinib (Cometriq).....	195
ABT-199.....	188	Carfilzomib (Kyprolis).....	196
Afatinib Dimaleate (Gilotrif).....	188	Cediranib.....	196
Afuresertib.....	189	Ceritinib (Zykadia) (LDK378).....	210
Alemtuzumab (Campath-1h).....	189	Cetuximab (Erbix).....	197
Alisertib.....	189	Cixutumumab.....	197
Amg 208 and 337.....	190	Combretastatin Disodium.....	198
Apatinib.....	190	Copanlisib.....	198
Axitinib (Inlyta).....	190	Crizotinib (Xalkori).....	198
Anetumab Ravtansine.....	191	Dabrafenib (Tafinlar).....	199
Bevacizumab (Avastin).....	191	Dacomitinib.....	199
BI 811283.....	192	Dactolisib.....	200
Bicalutamide (Casodex/Cosudex).....	192	Dasatinib (Sprycel).....	200
Blinatumomab.....	192	Denosumab (Xgeva).....	200
BMS-936559.....	193	Dovitinib.....	201
Bortezomib (Velcade).....	193	Elotuzumab.....	201
Bosutinib (Bosulif).....	193	Enzalutamide (Xtandi).....	201
Brentuximab Vedotin (Adcetris).....	194	Epratumumab.....	202
Brivonib Alaninate.....	194	Erismodegib.....	202
Buparlisib.....	195	Erlotinib (Tarceva).....	202
BYL719.....	195	Everolimus (Afinitor).....	203

Farletuzumab.....	203	Masitinib Mesylate.....	214
Figitumumab	204	Matuzumab	214
Foretinib	204	MEDI0639.....	214
Fostamatinib Disodium	204	MEK162.....	215
Ganitumab	205	Midostaurin.....	215
Gefitinib (Iressa).....	205	MK-0752.....	215
Gemtuzumab Ozogamicin (Mylotarg).....	206	MK-1775.....	216
GSK 2126458.....	206	MK-2206.....	216
Ibrutinib (Imbruvica).....	206	MK-8242.....	216
Idelalisib	207	MKC-1.....	217
Imatinib Mesylate (Gleevec).....	207	MSC2156119J.....	217
INC280.....	208	Navitoclax	217
Iniparib.....	208	Neratinib.....	218
Inotuzumab Ozogamicin.....	208	Nilotinib (Tasigna).....	218
Ipilimumab (Yervoy).....	209	Nimotuzumab.....	218
ISIS 481464.....	209	Nintedanib.....	219
Lapatinib Ditosylate (Tykerb).....	209	Niraparib	219
Lenalidomide (Revlimid).....	210	Nivolumab.....	219
Lenvatinib Mesylate	211	Ofatumumab (Arzerra).....	220
LGK974.....	211	Olaparib.....	220
Linifanib	211	OMP-54F28	220
Linsitinib	212	Onartuzumab	221
Lonafarnib	212	Orantinib	221
LOR-253 HCL.....	212	Pacritinib.....	221
LY2157299.....	213	Palbociclib	222
MABp1.....	213	Pomalidomide (Pomalyst).....	222
Mocetinostat.....	213	Panitumumab (Vectibix).....	222
		Panobinostat.....	223

Pazopanib Hydrochloride (Votrient).....	223
Perifosine.....	223
Pertuzumab (Perjeta).....	224
PF-03814735.....	224
Pimasertib.....	224
Ponatinib Hydrochloride (Iclusig).....	225
PRI-724.....	225
Quizartinib.....	226
R1507.....	226
Ramucirumab.....	226
Refametinib.....	226
Regorafenib (Stivarga).....	227
Reolysin*.....	227
Ridaforolimus.....	228
Rigosertib.....	228
Rilotumumab.....	228
Rituximab (Rituxan).....	228
Ruxolitinib Phosphate (Jakafi).....	229
Salirasib.....	229
Saracatinib.....	230
Selinexor.....	230
Selumetinib.....	231
Sirolimus (Rapamune).....	231

Sonolisib.....	231
Sorafenib (Nexavar).....	232
Sunitinib (Sutent).....	232
Telatinib.....	233
Temsirolimus (Torisel).....	233
Tipifarnib.....	233
Tivantinib.....	234
Trabedersen.....	234
Trametinib (Mekinist).....	234
Trastuzumab (Herceptin).....	235
Triciribine.....	236
Trebananib.....	236
Valproic Acid (Depakote).....	236
Vandetanib (Caprelsa).....	237
Vantictumab.....	237
Vemurafenib (Zelboraf).....	238
Vismodegib (Erivedge).....	238
Vorinostat (Zolinza).....	238
XL-147.....	239
Zalutumumab.....	239
Ziv-Aflibercept (Zaltrap).....	240

<i>Index</i>	241
--------------------	-----